Macromolecular crystallography plays a central role in biomedical research. At the University of Massachusetts Medical School, crystallographic analysis supports the research of more than 10 investigators. This instrumentation is used in the research that is supported by 13 NIH grants and trains more than 25 graduate students. Our current instrumentation can no longer be depended upon. Even when properly functioning the current instrumentation is incapable of serving the cutting-edge research programs many of the investigators require. A Shared Instrumentation Grant will allow us to purchase a new diffraction system and numerous programs will no longer be limited by an outdated machine. Specifically, we are requesting funds for a Rigaku HighFlux HomeLab x-ray diffraction system with an R-AXIS IV++ image plate detector. For many of our projects this new system will permit data acquisition that is sufficient to answer essential questions in macromolecular structure and drug design. For other research programs, the new system will allow local screening of crystals making synchrotron trips much more efficient. Thus the acquisition of this state-of-the-art crystallographic system will propel our research programs far beyond what we can currently achieve.

Public Health Relevance

Modern medicine requires an understanding of the detailed structures of biological molecules. In this proposal we request funds for an x-ray diffraction system, which will allow us to determine such key biological structures in atomic detail. These details will be used in drug design and in understanding the molecular mechanisms of many human diseases.

Agency
National Institute of Health (NIH)
Institute
Office of The Director, National Institutes of Health (OD)
Type
Biomedical Research Support Shared Instrumentation Grants (S10)
Project #
1S10OD012028-01
Application #
8247330
Study Section
Special Emphasis Panel (ZRG1-BCMB-K (30))
Program Officer
Levy, Abraham
Project Start
2012-04-01
Project End
2013-03-31
Budget Start
2012-04-01
Budget End
2013-03-31
Support Year
1
Fiscal Year
2012
Total Cost
$530,990
Indirect Cost
Name
University of Massachusetts Medical School Worcester
Department
Biochemistry
Type
Schools of Medicine
DUNS #
603847393
City
Worcester
State
MA
Country
United States
Zip Code
01655
Bellesis, Andrew G; Jecrois, Anne M; Hayes, Janelle A et al. (2018) Assembly of human C-terminal binding protein (CtBP) into tetramers. J Biol Chem 293:9101-9112
Kouno, Takahide; Silvas, Tania V; Hilbert, Brendan J et al. (2017) Crystal structure of APOBEC3A bound to single-stranded DNA reveals structural basis for cytidine deamination and specificity. Nat Commun 8:15024
Soumana, Djadé I; Kurt Yilmaz, Nese; Prachanronarong, Kristina L et al. (2016) Structural and Thermodynamic Effects of Macrocyclization in HCV NS3/4A Inhibitor MK-5172. ACS Chem Biol 11:900-9
Soumana, Djadé I; Kurt Yilmaz, Nese; Ali, Akbar et al. (2016) Molecular and Dynamic Mechanism Underlying Drug Resistance in Genotype 3 Hepatitis C NS3/4A Protease. J Am Chem Soc 138:11850-9
Hilbert, Brendan J; Morris, Benjamin L; Ellis, Keith C et al. (2015) Structure-guided design of a high affinity inhibitor to human CtBP. ACS Chem Biol 10:1118-27
Kolli, Madhavi; Ozen, Ay?egül; Kurt-Yilmaz, Nese et al. (2014) HIV-1 protease-substrate coevolution in nelfinavir resistance. J Virol 88:7145-54
Soumana, Djadé I; Ali, Akbar; Schiffer, Celia A (2014) Structural analysis of asunaprevir resistance in HCV NS3/4A protease. ACS Chem Biol 9:2485-90
Ragland, Debra A; Nalivaika, Ellen A; Nalam, Madhavi N L et al. (2014) Drug resistance conferred by mutations outside the active site through alterations in the dynamic and structural ensemble of HIV-1 protease. J Am Chem Soc 136:11956-63
Hilbert, Brendan J; Grossman, Steven R; Schiffer, Celia A et al. (2014) Crystal structures of human CtBP in complex with substrate MTOB reveal active site features useful for inhibitor design. FEBS Lett 588:1743-8
Nalam, Madhavi N L; Ali, Akbar; Reddy, G S Kiran Kumar et al. (2013) Substrate envelope-designed potent HIV-1 protease inhibitors to avoid drug resistance. Chem Biol 20:1116-24

Showing the most recent 10 out of 11 publications